Cargando…

A Genetic Score Associates With Pioglitazone Response in Patients With Non-alcoholic Steatohepatitis

Pioglitazone is used effectively to treat non-alcoholic steatohepatitis (NASH), but there is marked variability in response. This study examined whether genetic variation contributes to pioglitazone response variability in patients with NASH. This genetic substudy includes 55 participants of a rando...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kawaguchi-Suzuki, Marina, Cusi, Kenneth, Bril, Fernando, Gong, Yan, Langaee, Taimour, Frye, Reginald F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2018
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6056641/ https://www.ncbi.nlm.nih.gov/pubmed/30065651 http://dx.doi.org/10.3389/fphar.2018.00752

Ejemplares similares

Current clinical evidence on pioglitazone pharmacogenomics
por: Kawaguchi-Suzuki, Marina, et al.
Publicado: (2013)

Severity of non-alcoholic steatohepatitis is not linked to testosterone concentration in patients with type 2 diabetes
por: Dayton, Kristin Alexandra, et al.
Publicado: (2021)

Fructose and Non-Alcoholic Steatohepatitis
por: Roeb, Elke, et al.
Publicado: (2021)

Current, emerging, and potential therapies for non-alcoholic steatohepatitis
por: Yang, Zhen, et al.
Publicado: (2023)

Pioglitazone, quercetin and hydroxy citric acid effect on hepatic biomarkers in Non Alcoholic Steatohepatitis
por: Surapaneni, Krishna Mohan, et al.
Publicado: (2014)

Chymase Inhibitor as a Novel Therapeutic Agent for Non-alcoholic Steatohepatitis
por: Takai, Shinji, et al.
Publicado: (2018)

Noninvasive Diagnosis of Nonalcoholic Steatohepatitis and Advanced Liver Fibrosis Using Machine Learning Methods: Comparative Study With Existing Quantitative Risk Scores
por: Wu, Yonghui, et al.
Publicado: (2022)

Non-Alcoholic Steatohepatitis: A Review of Its Mechanism, Models and Medical Treatments
por: Peng, Cheng, et al.
Publicado: (2020)

Artemether Ameliorates Non-Alcoholic Steatohepatitis by Repressing Lipogenesis, Inflammation, and Fibrosis in Mice
por: Xu, Jia, et al.
Publicado: (2022)

Therapeutic effect of fenofibrate for non-alcoholic steatohepatitis in mouse models is dependent on regime design
por: Wang, Xinxue, et al.
Publicado: (2023)

The NLRP3 Inflammasome in Non-Alcoholic Fatty Liver Disease and Steatohepatitis: Therapeutic Targets and Treatment
por: Yu, Lili, et al.
Publicado: (2022)

Licorice extract inhibits the cGAS-STING pathway and protects against non-alcoholic steatohepatitis
por: Luo, Wei, et al.
Publicado: (2023)

Effect of pioglitazone, quercetin and hydroxy citric acid on extracellular matrix components in experimentally induced non-alcoholic steatohepatitis
por: Mohan, Surapaneni Krishna, et al.
Publicado: (2015)

MON-673 Use of Metabolic Syndrome Severity to Assess Treatment with Vitamin-E and Pioglitazone for Non-Alcoholic Steatohepatitis
por: DeBoer, Mark Daniel, et al.
Publicado: (2020)

Efficacy of SGLT2 Inhibitors Versus Pioglitazone in the Treatment of Non-alcoholic Fatty Liver Disease or Non-alcoholic Steatohepatitis: A Systematic Review
por: Kaur, Simran, et al.
Publicado: (2023)

Bicyclol attenuates high fat diet-induced non-alcoholic fatty liver disease/non-alcoholic steatohepatitis through modulating multiple pathways in mice
por: Wu, Jingyi, et al.
Publicado: (2023)

Cyclophilin Inhibitor NV556 Reduces Fibrosis and Hepatocellular Carcinoma Development in Mice With Non-Alcoholic Steatohepatitis
por: Kuo, Joseph, et al.
Publicado: (2019)

Berberine Alleviates Non-alcoholic Steatohepatitis Through Modulating Gut Microbiota Mediated Intestinal FXR Activation
por: Shu, Xiangbing, et al.
Publicado: (2021)

Rifaximin Ameliorates Non-alcoholic Steatohepatitis in Mice Through Regulating gut Microbiome-Related Bile Acids
por: Jian, Jie, et al.
Publicado: (2022)

Research landscape and frontiers of non-alcoholic steatohepatitis-associated hepatocellular carcinoma: a bibliometric and visual analysis
por: Gao, Bowen, et al.
Publicado: (2023)

Erratum: Bicyclol attenuates high fat diet-induced non-alcoholic fatty liver disease/non-alcoholic steatohepatitis through modulating multiple pathways in mice
por: Frontiers Production Office,
Publicado: (2023)

The Target MicroRNAs and Potential Underlying Mechanisms of Yiqi-Bushen-Tiaozhi Recipe against‐Non-Alcoholic Steatohepatitis
por: Hong, Wei, et al.
Publicado: (2020)

Extracts of Vine Tea Improve Diet-Induced Non-Alcoholic Steatohepatitis Through AMPK-LXRα Signaling
por: Chen, Yu-jun, et al.
Publicado: (2021)

Evaluation of the efficacy of mitochondrial fission inhibitor (Mdivi-1) using non-alcoholic steatohepatitis (NASH) liver organoids
por: Elbadawy, Mohamed, et al.
Publicado: (2023)

Metabolic Impact of Nonalcoholic Steatohepatitis in Obese Patients With Type 2 Diabetes
por: Lomonaco, Romina, et al.
Publicado: (2016)

MON-644 Prevalence of Non-Alcoholic Fatty Liver Disease and Liver Fibrosis in Patients with Type 2 Diabetes Mellitus
por: Fanous, Nada, et al.
Publicado: (2020)

New discriminant score to predict the fibrotic stage of non-alcoholic steatohepatitis in Japan
por: Kawamura, Yusuke, et al.
Publicado: (2015)

Medicinal Formula Huazhi-Rougan Attenuates Non-Alcoholic Steatohepatitis Through Enhancing Fecal Bile Acid Excretion in Mice
por: Li, Chunlin, et al.
Publicado: (2022)

Obeticholic acid and ferrostatin-1 differentially ameliorate non-alcoholic steatohepatitis in AMLN diet-fed ob/ob mice
por: Li, Shengjie, et al.
Publicado: (2022)

Gut-Derived Serotonin Contributes to the Progression of Non-Alcoholic Steatohepatitis via the Liver HTR2A/PPARγ2 Pathway
por: Wang, Lulu, et al.
Publicado: (2020)

Exploring the molecular mechanism of Gan Shuang granules for the treatment of non-alcoholic steatohepatitis using network pharmacology, molecular docking, and experimental verification
por: Zhi, Guoguo, et al.
Publicado: (2023)

Geniposide and Chlorogenic Acid Combination Ameliorates Non-alcoholic Steatohepatitis Involving the Protection on the Gut Barrier Function in Mouse Induced by High-Fat Diet
por: Peng, Jing-hua, et al.
Publicado: (2018)

Modification of a simple clinical scoring system as a diagnostic screening tool for non‐alcoholic steatohepatitis in Japanese patients with non‐alcoholic fatty liver disease
por: Nakamura, Akinobu, et al.
Publicado: (2013)

2235: Equipping health professional students to apply pharmacogenomic data to clinical decision making in real-world scenarios: Comparison of an active engagement Versus didactic teaching approach
por: Arwood, Meghan J., et al.
Publicado: (2018)

Genetic variants associated with steatohepatitis and liver fibrosis in HIV-infected patients with NAFLD
por: Busca, C., et al.
Publicado: (2022)

Combined alcoholic and non-alcoholic steatohepatitis
por: Ntandja Wandji, Line Carolle, et al.
Publicado: (2020)

PPAR‐γ‐induced changes in visceral fat and adiponectin levels are associated with improvement of steatohepatitis in patients with NASH
por: Gastaldelli, Amalia, et al.
Publicado: (2021)

Non-alcoholic steatohepatitis and risk of hepatocellular carcinoma
por: Rios, Rafael S., et al.
Publicado: (2021)

Kaempferol Alleviates Steatosis and Inflammation During Early Non-Alcoholic Steatohepatitis Associated With Liver X Receptor α-Lysophosphatidylcholine Acyltransferase 3 Signaling Pathway
por: Xiang, Hongjiao, et al.
Publicado: (2021)

Geniposide plus chlorogenic acid reverses non-alcoholic steatohepatitis via regulation of gut microbiota and bile acid signaling in a mouse model in vivo
por: Li, Hongshan, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_8v1phg5h2el32873pfop943sgb